Robert C Stein

List of Publications by Year
in descending order

92 papers	6,554 citations	76326 40 h-index	74163 75 g-index
95 all docs	95 docs citations	95 times ranked	8377 citing authors

#	Article	IF	Citations
1	Trastuzumab Beyond Progression in Human Epidermal Growth Factor Receptor 2–Positive Advanced Breast Cancer: A German Breast Group 26/Breast International Group 03-05 Study. Journal of Clinical Oncology, 2009, 27, 1999-2006.	1.6	685
2	Activation of the ATPase Activity of Hsp90 by the Stress-Regulated Cochaperone Aha1. Molecular Cell, 2002, 10, 1307-1318.	9.7	487
3	p110Â, a novel phosphoinositide 3-kinase in leukocytes. Proceedings of the National Academy of Sciences of the United States of America, 1997, 94, 4330-4335.	7.1	403
4	A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. British Journal of Cancer, 2006, 94, 828-834.	6.4	349
5	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
6	Three-dimensional in vitro tissue culture models of breast cancer — a review. Breast Cancer Research and Treatment, 2004, 85, 281-291.	2.5	268
7	Capivasertib Plus Paclitaxel Versus Placebo Plus Paclitaxel As First-Line Therapy for Metastatic Triple-Negative Breast Cancer: The PAKT Trial. Journal of Clinical Oncology, 2020, 38, 423-433.	1.6	240
8	Cloning of a human phosphoinositide 3-kinase with a C2 domain that displays reduced sensitivity to the inhibitor wortmannin. Biochemical Journal, 1997, 326, 139-147.	3.7	228
9	Proteomic definition of normal human luminal and myoepithelial breast cells purified from reduction mammoplasties. Proceedings of the National Academy of Sciences of the United States of America, 1999, 96, 12589-12594.	7.1	219
10	PI3-kinase inhibition: a target for drug development?. Trends in Molecular Medicine, 2000, 6, 347-358.	2.6	184
11	Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the Others. Journal of the National Cancer Institute, 2016, 108, djw050.	6.3	166
12	Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer, 2011, 47, 2273-2281.	2.8	164
13	Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO Journal, 2003, 22, 4178-4189.	7.8	139
14	Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial. Journal of Clinical Oncology, 2019, 37, 178-189.	1.6	136
15	Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin. Cancer Research, 2007, 67, 3239-3253.	0.9	135
16	Predictors of ovarian reserve in young women with breast cancer. British Journal of Cancer, 2007, 96, 1808-1816.	6.4	129
17	Human Phosphoinositide 3-Kinase C2Î², the Role of Calcium and the C2 Domain in Enzyme Activity. Journal of Biological Chemistry, 1998, 273, 33082-33090.	3.4	116
18	Prospects for phosphoinositide 3-kinase inhibition as a cancer treatment.. Endocrine-Related Cancer, 2001, 8, 237-248.	3.1	115

#	ARTICLE	IF	CITATIONS
19	Topical calcipotriol treatment in advanced breast cancer. Lancet, The, 1991, 337, 701-702.	13.7	109
20	The clinical and endocrine effects of 4-hydroxyandrostenedione alone and in combination with goserelin in premenopausal women with advanced breast cancer. British Journal of Cancer, 1990, 62, 679-683.	6.4	96
21	Tumour-Stromal Interactions in Breast Cancer: The Role of Stroma in Tumourigenesis. Tumor Biology, 2005, 26, 173-185.	1.8	95
22	Structural and functional diversity of phosphoinositide 3-kinases. Philosophical Transactions of the Royal Society B: Biological Sciences, 1996, 351, 217-223.	4.0	91
23	A preliminary clinical study of gossypol in advanced human cancer. Cancer Chemotherapy and Pharmacology, 1992, 30, 480-482.	2.3	90
24	POTENCY AND SELECTIVITY OF THE NON-STEROIDAL AROMATASE INHIBITOR CGS 16949A IN POSTMENOPAUSAL BREAST CANCER PATIENTS. Clinical Endocrinology, 1990, 32, 623-634.	2.4	82
25	Conveying Equipoise during Recruitment for Clinical Trials: Qualitative Synthesis of Clinicians' Practices across Six Randomised Controlled Trials. PLoS Medicine, 2016, 13, e1002147.	8.4	82
26	Aromatization inhibition alone or in combination with GnRH agonists for the treatment of premenopausal breast cancer patients. Journal of Steroid Biochemistry and Molecular Biology, 1992, 43, 155-159.	2.5	79
27	Economic Evaluation of Genomic Test–Directed Chemotherapy for Early-Stage Lymph Node–Positive Breast Cancer. Journal of the National Cancer Institute, 2012, 104, 56-66.	6.3	75
28	The NRG1 gene is frequently silenced by methylation in breast cancers and is a strong candidate for the 8p tumour suppressor gene. Oncogene, 2009, 28, 4041-4052.	5.9	74
29	Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochemical Journal, 2000, 348, 351-358.	3.7	69
30	The clinical effects of prolonged treatment of patients with advanced cancer with low-dose subcutaneous interleukin-2. British Journal of Cancer, 1991, 63, 275-278.	6.4	64
31	Models of breast cancer: is merging human and animal models the future?. Breast Cancer Research, 2003, 6, 22-30.	5.0	63
32	A double-blind study of the efficacy of metronidazole gel in the treatment of malodorous fungating tumours. European Journal of Cancer, 1992, 28, 888-889.	2.8	58
33	Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer in the randomised UK TACT2 trial (CRUK/05/19): a multicentre, phase 3, open-label, randomised, controlled trial. Lancet Oncology, The, 2017, 18, 929-945.	10.7	58
34	OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancer. Health Technology Assessment, 2016, 20, 1-202.	2.8	53
35	Treatment of advanced breast cancer in postmenopausal women with 4-hydroxyandrostenedione. Cancer Chemotherapy and Pharmacology, 1990, 26, 75-78.	2.3	52
36	AZD5363 plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (PAKT): A randomised, double-blind, placebo-controlled, phase II trial.. Journal of Clinical Oncology, 2018, 36, 1007-1007.	1.6	51

#	Article	IF	Citations
37	Solution structure of the C-terminal SH2 domain of the p85Î± regulatory subunit of phosphoinositide 3-kinase 1 1Edited by P. E. Wright. Journal of Molecular Biology, 1998, 276, 461-478.	4.2	50
38	The QuinteT Recruitment Intervention supported five randomized trials to recruit to target: a mixed-methods evaluation. Journal of Clinical Epidemiology, 2019, 106, 108-120.	5.0	49
39	Cluster analysis of an extensive human breast cancer cell line protein expression map database. Proteomics, 2002, 2, 212-223.	2.2	48
40	Development of a framework to improve the process of recruitment to randomised controlled trials (RCTs): the SEAR (Screened, Eligible, Approached, Randomised) framework. Trials, 2018, 19, 50.	1.6	48
41	IRIS study: a phase II study of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients. Breast Cancer Research and Treatment, 2017, 165, 343-353.	2.5	43
42	An endocrine and pharmacokinetic study of four oral doses of formestane in postmenopausal breast cancer patients. European Journal of Cancer, 1992, 28, 415-420.	2.8	37
43	Selecting Breast Cancer Patients for Chemotherapy: The Opening of the UK OPTIMA Trial. Clinical Oncology, 2013, 25, 109-116.	1.4	37
44	Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer: a systematic review and economic analysis. Health Technology Assessment, 2019, 23, 1-328.	2.8	35
45	Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim Trial. Value in Health, 2017, 20, 1311-1318.	0.3	31
46	A randomised prospective trial of surgical against medical tetracycline pleurodesis in the management of malignant pleural effusions secondary to breast cancer. European Journal of Cancer, 1993, 29, 316-319.	2.8	29
47	Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. Cancer Chemotherapy and Pharmacology, 1991, 27, 367-372.	2.3	28
48	The application of 2D gel-based proteomics methods to the study of breast cancer. Journal of Mammary Gland Biology and Neoplasia, 2002, 7, 385-393.	2.7	26
49	Macroscopic handling and reporting of breast cancer specimens preâ€•and postâ€•neoadjuvant chemotherapy treatment: review of pathological issues and suggested approaches. Histopathology, 2015, 67, 279-293.	2.9	26
50	An observational study showed that explaining randomization using gambling-related metaphors and computer-agency descriptions impeded randomized clinical trial recruitment. Journal of Clinical Epidemiology, 2018, 99, 75-83.	5.0	25
51	Phase I/II study of the anti-oestrogen zindoxifene (D16726) in the treatment of advanced breast cancer. A Cancer Research Campaign Phase I/II Clinical Trials Committee study. British Journal of Cancer, 1990, 61, 451-453.	6.4	23
52	Lactic acidosis. A presentation of metastatic breast cancer arising in pregnancy. Cancer, 1992, 69, 453-456.	4.1	21
53	Phosphatidylinositol 3-kinase, protein kinase B and ribosomal S6 kinases in the stimulation of thyroid epithelial cell proliferation by cAMP and growth factors in the presence of insulin. Biochemical Journal, 2000, 348, 351.	3.7	20
54	Epirubicin for pretreated advanced ovarian cancer. European Journal of Cancer & Clinical Oncology, 1990, 26, 850-851.	0.7	16

#	Article	IF	Citations
55	HER2 testing for breast carcinoma: recommendations for rapid diagnostic pathways in clinical practice. Journal of Clinical Pathology, 2014, 67, 161-167.	2.0	15
56	Adaptive designs for clinical trials assessing biomarker-guided treatment strategies. British Journal of Cancer, 2014, 110, 1950-1957.	6.4	15
57	Mitozantrone and methotrexate chemotherapy with and without mitomycin C in the treatment of advanced breast cancer: a randomised clinical trial. European Journal of Cancer, 1992, 28, 1963-1965.	2.8	10
58	Discrepancies in central review re-testing of patients with ER-positive and HER2-negative breast cancer in the OPTIMA prelim randomised clinical trial. British Journal of Cancer, 2017, 116, 859-863.	6.4	9
59	Informed consent in randomised controlled trials: development and preliminary evaluation of a measure of Participatory and Informed Consent (PIC). Trials, 2017, 18, 327.	1.6	9
60	A randomised study of carboplatin vs sequential ifosfamide/carboplatin for patients with FIGO stage III epithelial ovarian carcinoma. British Journal of Cancer, 1993, 68, 1190-1194.	6.4	8
61	Immunomodulatory agents: the cytokines. European Journal of Cancer, 1994, 30, 400-404.	2.8	7
62	Hyperpolarised ^{13}C MRI: a new horizon for non-invasive diagnosis of aggressive breast cancer. BJR|case Reports, 2019, 5, 20190026.	0.2	7
63	Viewpoint: Availability of oestrogen receptor and HER2 status for the breast multidisciplinary meeting discussion; time to get it right. European Journal of Surgical Oncology, 2016, 42, 994-998.	1.0	6
64	SH2 and SH3 Domains: Unraveling Signaling Networks with Peptide Antagonists. , 1998, 88, 187-196.		5
65	Combinatorial use of mRNA and two-dimensional electrophoresis expression data to choose relevant features for mass spectrometric identification. Proteomics, 2002, 2, 1464-1473.	2.2	5
66	Abstract S3-3: The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019). , 2012, , .		5
67	A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) â€" Trial Results.. Journal of Clinical Oncology, 2016, 34, 549-549.	1.6	5
68	Analysis of Gossypol Enantiomers in Human Serum. Journal of Liquid Chromatography and Related Technologies, 1990, 13, 2261-2268.	1.0	4
69	Abstract P4-11-07: Comparison of multiparameter tests in the UK OPTIMA-Prelim trial. , 2015, , .		4
70	OPTIMA (Optimal Personalised Treatment of early breast cancer usIng Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions.. Journal of Clinical Oncology, 2016, 34, TPS623-TPS623.	1.6	4
71	Clinical oncology: Case presentations from oncology centres 1. Ewing's sarcoma. European Journal of Cancer & Clinical Oncology, 1991, 27, 1525-1533.	0.7	3
72	Comparison of ondansetron with dexamethasone and domperidone in the prophylaxis of non-cisplatin chemotherapy induced emesis refractory to dexamethasone. European Journal of Cancer & Clinical Oncology, 1991, 27, 302-303.	0.7	3

#	ARTICLE	IF	CITATIONS
73	Functional Proteomic Analysis of Long-term Growth Factor Stimulation and Receptor Tyrosine Kinase Coactivation in Swiss 3T3 Fibroblasts. Molecular and Cellular Proteomics, 2012, 11, 1690-1708.	3.8	3
74	Abstract OT1-03-13: A phase II, double blind, randomised, placebo-controlled study of the AKT Inhibitor AZD5363 in combination with paclitaxel in triple-negative advanced or metastatic breast cancer (TNBC)(NCT02423603). , 2016, , .		3
75	Computational approaches to support comparative analysis of multiparametric tests: Modelling versus Training. PLoS ONE, 2020, 15, e0238593.	2.5	2
76	Nonmetastatic manifestations of malignancy: hormonal. Palliative Medicine, 1989, 3, 189-196.	3.1	1
77	A phase II study of ifosfamide and bleomycin in advanced or recurrent cervical carcinoma. International Journal of Gynecological Cancer, 1996, 6, 323-327.	2.5	1
78	Efficient design of a phase III trial of competing tests for personalised cancer treatment in the absence of gold standard outcome data: challenges and potential solutions. Trials, 2013, 14, .	1.6	1
79	1809 Results of the OPTIMA (Optimal Personalized Treatment of early breast cancer usIng) Tj ETQq1 1 0.784314 rgBT /Overlock 10 T	2.8	1
80	Abstract OT3-02-02: ROSCO: A randomised phase III, stratified CEP17/TOP2A biomarker trial of neo-adjuvant 5-flourouracil, epirubicin and cyclophosphamide vs docetaxel and cyclophosphamide chemotherapy. , 2016, , .		1
81	Abstract PD2-02: NEO-EXCEL phase III neoadjuvant trial of pre-operative exemestane or letrozole +/-celecoxib in the treatment of ER positive postmenopausal early breast cancer. , 2016, , .		1
82	Assessment of response to treatment during chemotherapy for breast cancer. A new role for breast MRI?. Breast, 1997, 6, 319-320.	2.2	0
83	Using adaptive designs for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests. Trials, 2013, 14, O12.	1.6	0
84	An adaptive biomarker strategy clinical trial design. Trials, 2013, 14, .	1.6	0
85	The use of early decision modelling and value of information analysis in an adaptive trial design: results from the OPTIMA preliminary study. Trials, 2015, 16, .	1.6	0
86	Practicalities of using an adaptive design for decision making within the optima trial: optimal personalized treatment of early breast cancer using multi-parameter tests. Trials, 2015, 16, .	1.6	0
87	OPTIMA (Optimal Personalised Treatment of early breast cancer using Multi-parameter Analysis): A prospective trial to validate the predictive utility and cost-effectiveness of gene expression test-directed chemotherapy decisions. European Journal of Surgical Oncology, 2016, 42, S9-S10.	1.0	0
88	OP66 Tumor Profiling Tests In Early Breast Cancer: A Systematic Review. International Journal of Technology Assessment in Health Care, 2018, 34, 24-24.	0.5	0
89	Comparative survival analysis of multiparametric testsâ€"when molecular tests disagreeâ€"A TEAM Pathology study. Npj Breast Cancer, 2021, 7, 90.	5.2	0
90	Abstract P6-08-11: UK OPTIMA-prelim study demonstrates economic value in more clinical evaluation of multi-parameter prognostic tests in early breast cancer. , 2015, , .		0

#	Article	IF	Citations
91	Abstract OT3-02-12: OPTIMA (optimal personalised treatment of early breast cancer usIng) Tj ETQq1 1 0.784314 rgBT /Overlock 10 Tf 5 of gene expression test-directed chemotherapy decisions. , 2016, , .		0
92	Abstract OT3-17-01: OPTIMA: A prospective randomized trial to validate the clinical utility and cost-effectiveness of gene expression test-directed chemotherapy decisions in mostly node-positive early breast cancer. , 2020, , .		0